80_FR_29111 80 FR 29014 - Government-Owned Inventions; Availability for Licensing

80 FR 29014 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 80, Issue 97 (May 20, 2015)

Page Range29014-29015
FR Document2015-12124

The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

Federal Register, Volume 80 Issue 97 (Wednesday, May 20, 2015) 
[Federal Register Volume 80, Number 97 (Wednesday, May 20, 2015)]
[Notices]
[Pages 29014-29015]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-12124]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the U.S. patent applications listed below may be obtained by writing to 
the indicated licensing contact at the Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to 
receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology descriptions follow.

A Novel Therapeutic Vector for Hemoglobin Disorders

    Description of Technology: Investigators at the National Heart, 
Lung, and Blood Institute have designed a novel lentiviral vector as a 
potential gene therapy for sickle cell anemia and beta-thalassemia. The 
novel lentiviral vector encodes the beta-globin gene in a forward 
orientation and can produce 5-10 fold higher viral titer and 4-10 fold 
higher gene transfer efficiency to hematopoietic stem cells than 
reverse-oriented lentiviral vectors. In vivo studies conducted in 
rhesus macaques show beta-globin production after transplantation with 
this novel lentiviral vector. This technology could provide an 
alternative therapy for patients suffering from blood disorders 
associated with beta-globin gene mutations.
    Potential Commercial Applications: Gene therapy.
    Competitive Advantages:
     Increased viral titers
     Increased transduction efficiency
     Large scale vector production
    Development Stage:
     Early-stage
     In vitro data available
     In vivo data available (animal)
    Inventors: Naoya Uchida and John F. Tisdale (NHLBI).
    Intellectual Property: HHS Reference No. E-165-2014/0--U.S. 
Provisional Application No. 62/048,881 filed September 11, 2014.
    Licensing Contact: Cristina Thalhammer-Reyero, Ph.D.; 301-495-4507; 
[email protected].
    Collaborative Research Opportunity: The National Heart, Lung and 
Blood Institute is seeking statements of capability or interest from 
parties interested in collaborative research to further develop, 
evaluate or commercialize this technology. For collaboration 
opportunities, please contact Denise Crooks at [email protected].

[[Page 29015]]

X-Clometer: Optimizing Portable Radiography

    Description of Technology: The technology offered for licensing and 
commercial development relates to a method and apparatus that can 
significantly improve the diagnostic performance of portable chest 
(CXR) and abdominal x-rays. This device quantifies angulation of a 
patient to provide for a better comparison of day-to-day improvement.
    The portable CXR is one of the most commonly requested diagnostic 
medical tests around the world. They are performed nearly daily on some 
of the sickest patients in hospitals. Paradoxically, it is well 
documented that portable radiography of the chest is inconsistent and 
often inadequate.
    An upright projection best evaluates effusions, rules out free air, 
or detects air-fluid levels. Optimally, the images are obtained at 
similar angles each day, even if not erect, to allow accurate 
comparisons and assessment of change. It is well documented that 
portable radiography of the chest is inconsistent and often inadequate. 
To achieve optimal quality of the exam the technologist attempts the 
most upright projection; balanced with patient condition and ability to 
achieve this often impossible task.
    Potential Commercial Applications: Portable chest and abdominal x-
rays performed at patient's hospital bedside.
    Competitive Advantages:
     Currently, there is no quantitative marker to indicate 
degree of the upright position. Prior markers with small ball bearings 
sinking to a small circle only indicate if the patient is supine or 
not. This technology introduces a simple dynamic marker that can 
quantify the angle at a glance for the radiologist to best compare 
patient condition over time. This device objectively quantifies 
cassette angle with a ball bearing in a cylindrical tube with markers 
to indicate upright position in degrees.
     The technology improves performance of CXR, allowing 
reliable comparisons of patient condition over time. Thus, better 
therapies can be planned and unnecessary CT (Computerized Tomography) 
can be prevented.
     The technology improves care for Intensive Care Unit 
patients, as developing effusion and the need for immediate drainage 
(as one of many examples) can be more effectively assessed with the 
present apparatus. A widespread use of the device will save lives 
through improved diagnosis and comparison of effusions.
    Development Stage:
     A performance of a visual prototype was demonstrated. The 
visual prototype was imaged at 5 selected angles with a chest phantom. 
Initial in-vitro results demonstrate that angles can be quantified to 
within 30 degrees.
     Improved prototypes with more accuracy are currently being 
manufactured for to patient use. In-vivo studies will soon be underway 
to validate clinical utility.
    Inventors: Les R. Folio (CC) and Lucas S. Folio
    Publications:

1. Wandtke JC. Bedside chest radiography. Radiology. 1994; 190:1-10. 
[PMID 8043058]
2. Pneumatikos I, Bouros D. Pleural effusions in critically ill 
patients. Respiration. 2008; 76(3):241-248. [PMID 18824883]
3. Mattison LE, et al. Pleural effusions in the medical ICU: 
Prevalence, causes, and clinical implications. Chest. 1997 
Apr;111(4):1018-1023. [PMID 9106583]
4. Fartoukh M, et al. Clinically documented pleural effusions in 
medical ICU patients: How useful is routine thoracentesis? Chest. 
2002 Jan;121(1):178-184. [PMID 11796448]
5. Bekemeyer WB, et al. Efficacy of chest radiography in a 
respiratory intensive care unit. A prospective study. Chest. 1985 
Nov; 88(5): 691-696. [PMID: 4053711]
6. Tocino I. Chest imaging in intensive care unit. Eur J Radiol 1996 
Aug;23(1):46-57. [PMID 8872073]

    Patent Status: HHS Reference No. E-036-2011/0--U.S. Patent 
Application No. 14/005,024 filed September 13, 2013.
    Licensing Contact: Tedd Fenn; 424-297-0336; [email protected]
    Collaborative Research Opportunity: The NIH Clinical Center, 
Radiology and Imaging Sciences, is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate, or commercialize X-Clometer. Please contact Ken 
Rose, Ph.D. at 240-276-5509 or [email protected] for more information.

    Dated: May 14, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of 
Health.
[FR Doc. 2015-12124 Filed 5-19-15; 8:45 am]
BILLING CODE 4140-01-P

29014 Federal Register / Vol. 80, No. 97 / Wednesday, May 20, 2015 / Notices Group; Radiation Therapeutics and Biology Scientific Review, National Institutes of for companies and may also be available Study Section. Health, 6701 Rockledge Drive, Room 6170, for licensing. Date: June 15–16, 2015. MSC 7892, Bethesda, MD 20892, 301–435– FOR FURTHER INFORMATION CONTACT: Time: 8:00 a.m. to 4:00 p.m. 4514, bleasdaleje@csr.nih.gov. Agenda: To review and evaluate grant Licensing information and copies of the Name of Committee: Molecular, Cellular applications. U.S. patent applications listed below and Developmental Neuroscience Integrated Place: Embassy Suites at the Chevy Chase Review Group; Synapses, Cytoskeleton and may be obtained by writing to the Pavilion, 4300 Military Road NW., Trafficking Study Section. indicated licensing contact at the Office Washington, DC 20015. Date: June 18–19, 2015. of Technology Transfer, National Contact Person: Bo Hong, Ph.D., Scientific Time: 8:30 a.m. to 4:00 p.m. Institutes of Health, 6011 Executive Review Officer, Center for Scientific Review, Agenda: To review and evaluate grant Boulevard, Suite 325, Rockville, National Institutes of Health, 6701 Rockledge applications. Maryland 20852–3804; telephone: 301– Drive, Room 6194, MSC 7804, Bethesda, MD Place: Hotel Monaco Alexandria, 480 King 20892, 301–996–6208, hongb@csr.nih.gov. 496–7057; fax: 301–402–0220. A signed Street, Alexandria, VA 22314. Confidential Disclosure Agreement will Name of Committee: Biobehavioral and Contact Person: Christine A Piggee, Ph.D., Behavioral Processes Integrated Review be required to receive copies of the Scientific Review Officer, Center for Group; Motor Function, Speech and Scientific Review, National Institutes of patent applications. Rehabilitation Study Section. Health, 6701 Rockledge Drive, Room 4186, SUPPLEMENTARY INFORMATION: Date: June 15, 2015. MSC 7850, Bethesda, MD 20892, 301–435– Technology descriptions follow. Time: 8:00 a.m. to 6:00 p.m. 0657, christine.piggee@nih.gov. Agenda: To review and evaluate grant A Novel Therapeutic Vector for Name of Committee: Center for Scientific applications. Review Special Emphasis Panel, Traumatic Hemoglobin Disorders Place: St. Gregory Hotel, 2033 M Street Brain Injury and Cerebrovascular Disorders. Description of Technology: NW., Washington, DC 20036. Date: June 19, 2015. Investigators at the National Heart, Contact Person: Biao Tian, Ph.D., Scientific Time: 1:00 p.m. to 3:00 p.m. Review Officer, Center for Scientific Review, Lung, and Blood Institute have designed Agenda: To review and evaluate grant a novel lentiviral vector as a potential National Institutes of Health, 6701 Rockledge applications. Drive, Room 3166, MSC 7848, Bethesda, MD gene therapy for sickle cell anemia and Place: National Institutes of Health, 6701 20892, 301–402–4411, tianbi@csr.nih.gov. Rockledge Drive, Bethesda, MD 20892 beta-thalassemia. The novel lentiviral Name of Committee:Oncology 2— (Telephone Conference Call). vector encodes the beta-globin gene in a Translational Clinical Integrated Review Contact Person: Alexander Yakovlev, forward orientation and can produce 5– Group; Cancer Biomarkers Study Section. Ph.D., Scientific Review Officer, Center for 10 fold higher viral titer and 4–10 fold Date: June 17, 2015. Scientific Review, National Institutes of higher gene transfer efficiency to Time: 8:00 a.m. to 6:00 p.m. Health, 6701 Rockledge Drive, Room 5206, hematopoietic stem cells than reverse- Agenda: To review and evaluate grant MSC 7846, Bethesda, MD 20892–7846, 301– oriented lentiviral vectors. In vivo applications. 435–1254, yakovleva@csr.nih.gov. studies conducted in rhesus macaques Place: Embassy Suites at the Chevy Chase (Catalogue of Federal Domestic Assistance Pavilion, 4300 Military Road NW., show beta-globin production after Program Nos. 93.306, Comparative Medicine; transplantation with this novel Washington, DC 20015. 93.333, Clinical Research, 93.306, 93.333, Contact Person: Lawrence Ka-Yun Ng, lentiviral vector. This technology could 93.337, 93.393–93.396, 93.837–93.844, Ph.D., Scientific Review Officer, Center for 93.846–93.878, 93.892, 93.893, National provide an alternative therapy for Scientific Review, National Institutes of Institutes of Health, HHS) patients suffering from blood disorders Health, 6701 Rockledge Drive, Room 6152, associated with beta-globin gene MSC 7804, Bethesda, MD 20892, 301–357– Dated: May 15, 2015. mutations. 9318, ngkl@csr.nih.gov. Anna Snouffer, Potential Commercial Applications: Name of Committee: Endocrinology, Deputy Director, Office of Federal Advisory Gene therapy. Metabolism, Nutrition and Reproductive Committee Policy. Competitive Advantages: Sciences Integrated Review Group; Cellular [FR Doc. 2015–12242 Filed 5–19–15; 8:45 am] • Increased viral titers Aspects of Diabetes and Obesity Study BILLING CODE 4140–01–P • Increased transduction efficiency Section. • Large scale vector production Date: June 18, 2015. Development Stage: Time: 8:00 a.m. to 6:00 p.m. DEPARTMENT OF HEALTH AND • Early-stage Agenda: To review and evaluate grant • In vitro data available applications. HUMAN SERVICES • In vivo data available (animal) Place: Doubletree Hotel Bethesda Inventors: Naoya Uchida and John F. (Formerly Holiday Inn Select), 8120 National Institutes of Health Wisconsin Avenue, Bethesda, MD 20814. Tisdale (NHLBI). Contact Person: Alexander D Politis, Ph.D., Government-Owned Inventions; Intellectual Property: HHS Reference Scientific Review Officer, Center for Availability for Licensing No. E–165–2014/0—U.S. Provisional Scientific Review, National Institutes of Application No. 62/048,881 filed Health, 6701 Rockledge Drive, Room 3210, AGENCY: National Institutes of Health, September 11, 2014. MSC 7808, Bethesda, MD 20892, (301) 435– HHS. Licensing Contact: Cristina 1150, politisa@csr.nih.gov. ACTION: Notice. Thalhammer-Reyero, Ph.D.; 301–495– Name of Committee: Endocrinology, 4507; thalhamc@mail.nih.gov. Metabolism, Nutrition and Reproductive SUMMARY: The inventions listed below Collaborative Research Opportunity: Sciences Integrated Review Group; Molecular are owned by an agency of the U.S. The National Heart, Lung and Blood and Cellular Endocrinology Study Section. mstockstill on DSK4VPTVN1PROD with NOTICES Government and are available for Institute is seeking statements of Date: June 18, 2015. licensing in the U.S. in accordance with capability or interest from parties Time: 8:00 a.m. to 6:00 p.m. interested in collaborative research to 35 U.S.C. 209 and 37 CFR part 404 to Agenda: To review and evaluate grant applications. achieve expeditious commercialization further develop, evaluate or Place: Residence Inn Bethesda, 7335 of results of federally-funded research commercialize this technology. For Wisconsin Avenue, Bethesda, MD 20814. and development. Foreign patent collaboration opportunities, please Contact Person: John Bleasdale, Ph.D., applications are filed on selected contact Denise Crooks at crooksd@ Scientific Review Officer, Center for inventions to extend market coverage mail.nih.gov. VerDate Sep<11>2014 23:50 May 19, 2015 Jkt 235001 PO 00000 Frm 00086 Fmt 4703 Sfmt 4703 E:\FR\FM\20MYN1.SGM 20MYN1

Federal Register / Vol. 80, No. 97 / Wednesday, May 20, 2015 / Notices 29015 X-Clometer: Optimizing Portable • A performance of a visual prototype amended (5 U.S.C. App.), notice is Radiography was demonstrated. The visual prototype hereby given of the following meetings. Description of Technology: The was imaged at 5 selected angles with a The meetings will be closed to the technology offered for licensing and chest phantom. Initial in-vitro results public in accordance with the commercial development relates to a demonstrate that angles can be provisions set forth in sections method and apparatus that can quantified to within 30 degrees. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., • Improved prototypes with more as amended. The grant applications and significantly improve the diagnostic accuracy are currently being the discussions could disclose performance of portable chest (CXR) and manufactured for to patient use. In-vivo confidential trade secrets or commercial abdominal x-rays. This device quantifies studies will soon be underway to property such as patentable material, angulation of a patient to provide for a validate clinical utility. and personal information concerning better comparison of day-to-day Inventors: Les R. Folio (CC) and Lucas individuals associated with the grant improvement. S. Folio applications, the disclosure of which The portable CXR is one of the most Publications: commonly requested diagnostic medical would constitute a clearly unwarranted tests around the world. They are 1. Wandtke JC. Bedside chest radiography. invasion of personal privacy. Radiology. 1994; 190:1–10. [PMID performed nearly daily on some of the Name of Committee: Infectious Diseases 8043058] sickest patients in hospitals. and Microbiology Integrated Review Group; 2. Pneumatikos I, Bouros D. Pleural effusions Paradoxically, it is well documented Virology—A Study Section. in critically ill patients. Respiration. that portable radiography of the chest is Date: June 8–9, 2015. 2008; 76(3):241–248. [PMID 18824883] Time: 8:00 a.m. to 5:00 p.m. inconsistent and often inadequate. 3. Mattison LE, et al. Pleural effusions in the Agenda: To review and evaluate grant An upright projection best evaluates medical ICU: Prevalence, causes, and clinical implications. Chest. 1997 applications. effusions, rules out free air, or detects Place: Renaissance Long Beach Hotel, 111 air-fluid levels. Optimally, the images Apr;111(4):1018–1023. [PMID 9106583] 4. Fartoukh M, et al. Clinically documented East Ocean Blvd., Long Beach, CA 90802. are obtained at similar angles each day, pleural effusions in medical ICU Contact Person: Kenneth M. Izumi, Ph.D., even if not erect, to allow accurate patients: How useful is routine Scientific Review Officer, Center for comparisons and assessment of change. thoracentesis? Chest. 2002 Scientific Review, National Institutes of It is well documented that portable Jan;121(1):178–184. [PMID 11796448] Health, 6701 Rockledge Drive, Room 3204, radiography of the chest is inconsistent 5. Bekemeyer WB, et al. Efficacy of chest MSC 7808, Bethesda, MD 20892, 301–496– radiography in a respiratory intensive 6980, izumikm@csr.nih.gov. and often inadequate. To achieve optimal quality of the exam the care unit. A prospective study. Chest. Name of Committee: Musculoskeletal, Oral 1985 Nov; 88(5): 691–696. [PMID: and Skin Sciences Integrated Review Group; technologist attempts the most upright 4053711] Skeletal Muscle and Exercise Physiology projection; balanced with patient Study Section. 6. Tocino I. Chest imaging in intensive care condition and ability to achieve this unit. Eur J Radiol 1996 Aug;23(1):46–57. Date: June 10–11, 2015. often impossible task. [PMID 8872073] Time: 8:00 a.m. to 6:00 p.m. Potential Commercial Applications: Agenda: To review and evaluate grant Portable chest and abdominal x-rays Patent Status: HHS Reference No. E– applications. performed at patient’s hospital bedside. 036–2011/0—U.S. Patent Application Place: Historic Inns of Annapolis, 58 State Competitive Advantages: No. 14/005,024 filed September 13, Circle, Annapolis, MD 21401. • Currently, there is no quantitative 2013. Contact Person: Richard Ingraham, Ph.D., Licensing Contact: Tedd Fenn; 424– Scientific Review Officer, Center for marker to indicate degree of the upright 297–0336; tedd.fenn@nih.gov Scientific Review, National Institutes of position. Prior markers with small ball Collaborative Research Opportunity: Health, 6701 Rockledge Drive, Room 4116, bearings sinking to a small circle only MSC 7814, Bethesda, MD 20892, 301–496– The NIH Clinical Center, Radiology and indicate if the patient is supine or not. 8551, ingrahamrh@mail.nih.gov. Imaging Sciences, is seeking statements This technology introduces a simple Name of Committee: Oncology 1-Basic of capability or interest from parties dynamic marker that can quantify the Translational Integrated Review Group; interested in collaborative research to angle at a glance for the radiologist to Cancer Etiology Study Section. further develop, evaluate, or best compare patient condition over Date: June 11–12, 2015. commercialize X-Clometer. Please time. This device objectively quantifies Time: 8:00 a.m. to 5:00 p.m. contact Ken Rose, Ph.D. at 240–276– Agenda: To review and evaluate grant cassette angle with a ball bearing in a 5509 or rosek@mail.nih.gov for more applications. cylindrical tube with markers to information. Place: Gaithersburg Marriott indicate upright position in degrees. Washingtonian Center, 9751 Washingtonian • The technology improves Dated: May 14, 2015. Richard U. Rodriguez, Boulevard, Gaithersburg, MD 20878. performance of CXR, allowing reliable Contact Person: Svetlana Kotliarova, Ph.D., comparisons of patient condition over Acting Director, Office of Technology Scientific Review Officer, Center for time. Thus, better therapies can be Transfer, National Institutes of Health. Scientific Review, National Institutes of planned and unnecessary CT [FR Doc. 2015–12124 Filed 5–19–15; 8:45 am] Health, 6701 Rockledge Drive, Room 6214, (Computerized Tomography) can be BILLING CODE 4140–01–P Bethesda, MD 20892, 301–594–7945, prevented. kotliars@mail.nih.gov. • The technology improves care for Name of Committee: Center for Scientific Intensive Care Unit patients, as DEPARTMENT OF HEALTH AND Review Special Emphasis Panel; Member HUMAN SERVICES Conflict: Palliative care and survivorship. mstockstill on DSK4VPTVN1PROD with NOTICES developing effusion and the need for immediate drainage (as one of many Date: June 11, 2015. National Institutes of Health Time: 6:00 p.m. to 8:00 p.m. examples) can be more effectively Agenda: To review and evaluate grant assessed with the present apparatus. A applications. Center for Scientific Review Notice of widespread use of the device will save Place: Renaissance Long Beach Hotel, 111 Closed Meetings lives through improved diagnosis and East Ocean Blvd., Long Beach, CA 90802. comparison of effusions. Pursuant to section 10(d) of the Contact Person: Martha L. Hare, Ph.D., RN, Development Stage: Federal Advisory Committee Act, as Scientific Review Officer, Center for VerDate Sep<11>2014 23:50 May 19, 2015 Jkt 235001 PO 00000 Frm 00087 Fmt 4703 Sfmt 4703 E:\FR\FM\20MYN1.SGM 20MYN1


Document Created: 2018-02-21 10:29:41
Document Modified: 2018-02-21 10:29:41
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
ContactLicensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402- 0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.
FR Citation80 FR 29014 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR